An immunotherapy for metastatic pancreatic cancer has led to an "ongoing, durable, complete response" in a human patient 6 months after treatment. The therapy, based on a type of white blood cell called natural killer cells, was successful in a phase 1 clinical trial and is entering phase 2 trials.